Vistagen Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-31. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
In accordance with this plan, upon Dr. Williamson's appointment to the Board, Dr. Williamson received stock options issued under the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended (the " Options "), to purchase up to 40,826 shares of the Company's common stock, par value $0.001 per share (" Common Stoc k"), at an exercise price of $0.2433 per share, an amount equal to the closing price of the Company's Common Stock on Dr. Williamson's appointment date (the " Effective Date ").
Reported
On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the " Company "), notified the Company of her decision not to stand for re-election at the Company's 2026 Annual Meeting of Stockholders (the " 2026 Annual Meeting ").
Appointed: Angel S. Angelov, Chief Medical Officer
On May 18, 2026 (the " Effective Date "), Vistagen Therapeutics, Inc. (the " Company ") appointed Angel S. Angelov, M.D., MBA to serve as the Company's Chief Medical Officer.
Find people with the same kind of experience as the Chief Medical Officer at Vistagen Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at Vistagen Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Vistagen Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Vistagen Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Vistagen Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.